Logo Logo
Switch Language to German
Arnold, M. -L.; Bach, C.; Heinemann, F. M.; Horn, P. A.; Ziemann, M.; Lachmann, N.; Muehlbacher, A.; Dick, A.; Ender, A.; Thammanichanond, D.; Schaub, S.; Honger, G.; Fischer, G. F.; Mytilineos, J.; Hallensleben, M.; Hitzler, W. E.; Seidl, C.; Spriewald, B. M. (2018): Anti-HLA alloantibodies of the IgA isotype in re-transplant candidates part II: Correlation with graft survival. In: International Journal of Immunogenetics, Vol. 45, No. 3: pp. 95-101
Full text not available from 'Open Access LMU'.


We reported previously on the widespread occurrence of anti-HLA alloantibodies of the IgA isotype (anti-HLA IgA) in the sera of solid-organ re-transplantation (re-tx) candidates (Arnold etal., ). Specifically focussing on kidney re-tx patients, we now extended our earlier findings by examining the impact of the presence and donor specificity of anti-HLA IgA on graft survival. We observed frequent concurrence of anti-HLA IgA and anti-HLA IgG in 27% of our multicenter collective of 694 kidney re-tx patients. This subgroup displayed significantly reduced graft survival as evidenced by the median time to first dialysis after transplantation (TTD 77months) compared to patients carrying either anti-HLA IgG or IgA (TTD 102 and 94months, respectively). In addition, donor specificity of anti-HLA IgA had a significant negative impact on graft survival (TTD 74months) in our study. Taken together, our data strongly indicate that presence of anti-HLA IgA, in particular in conjunction with anti-HLA-IgG, in sera of kidney re-tx patients is associated with negative transplantation outcome.